iPath Goldman Sachs Barclays Bank PLC iPath Exchange Traded Notes Linked to the CBOE S&P 500 BuyWrite Index Structured Product (BWV): Price and Financial Metrics ETF

iPath Goldman Sachs Barclays Bank PLC iPath Exchange Traded Notes Linked to the CBOE S&P 500 BuyWrite Index Structured Product (BWV): $0.80

0.01 (+0.96%)

POWR Rating

Component Grades

Buy & Hold

F

Peer

D

Add BWV to Watchlist
Sign Up

Category: Large Cap Blend ETFs

Category

C

Ranked


in category

BWV Price/Volume Stats - 7 Best ETFs for the NEXT Bull Market

Current price $0.80 52-week high $8.00
Prev. close $0.79 52-week low $0.76
Day low $0.77 Volume 20,090
Day high $0.82 Avg. volume 1,042,255
50-day MA $1.00 Dividend yield N/A
200-day MA $1.39

BWV Stock Price Chart Interactive Chart >


iPath Goldman Sachs Barclays Bank PLC iPath Exchange Traded Notes Linked to the CBOE S&P 500 BuyWrite Index Structured Product (BWV) ETF Bio


The investment objective of the iPath CBOE S&P 500 BuyWrite ETN is to provide investors with exposure to the CBOE S&P 500 BuyWrite Index. The Index is designed to measure the total rate of return on a hypothetical "buy-write”, or "covered call", strategy on the S&P 500® Index. This strategy consists of a hypothetical portfolio consisting of a "long” position indexed to the S&P 500 Index and the sale of a succession of a one-month, at-the-money S&P 500® call options that are listed on the Chicago Board Options Exchange.

BWV ETF Info

Issuer
Expense Ratio %
Asset Class
Sector Large Cap Blend ETFs
Assets Under Management (AUM) N/A
Net Asset Value (NAV) $0.00
Options? No
Total Holdings N/A

BWV Top Holdings

Symbol Company % of Total
%
%
%
%
%
%
%
%
%
%

Latest BWV News From Around the Web

Below are the latest news stories about BLUE WATER BIOTECH INC that investors may wish to consider to help them evaluate BWV as an investment opportunity.

Blue Water Vaccines GAAP EPS of -$0.18 misses by $0.03

  • Blue Water Vaccines press release (NASDAQ:BWV): Q1 GAAP EPS of -$0.18 misses by $0.03.
  • Cash was $20.3 million as of March 31, 2023, as compared to $25.8 million as of December 31, 2022. The decrease was primarily due to an increase in various business activities to support company growth, as well as increased research and development activities.
...

Seeking Alpha | May 15, 2023

Blue Water Biotech Reports First Quarter 2023 Financial Results and Recent Business Highlights

CINCINNATI, May 12, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”), a biotechnology company spanning multiple sectors, today announced its financial results for the quarter ended March 31, 2023 and provided an update on recent business developments and Company progress. Blue Water Biotech is a biological and pharmaceutical technology company developing multiple preclinical vaccine candidates across various infectious diseases and owns the FDA-approved benign hy

Yahoo | May 12, 2023

Blue Water Biotech to Present Corporate Overview and ENTADFI® Launch Plan at the JMP Securities Life Sciences Conference in New York, NY

CINCINNATI, May 10, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”), a biopharmaceutical company developing transformational therapies to address significant global health challenges, today announced that Blue Water management will present at the JMP Securities Life Sciences Conference at the New York Hilton Midtown on Monday, May 15th at 3:30pm EDT. Session details are as follows: Date:Monday, May 15th, 2023Time:3:30pm EDTLocation:New York Hilton Midtown, Room

Yahoo | May 10, 2023

Blue Water Biotech Appoints Board-Certified Urologist Jay Newmark, M.D., MBA as Chief Medical Officer

CINCINNATI, April 26, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”), a biotechnology company spanning multiple sectors, today announced the appointment of Jay Newmark, M.D., MBA as the Company’s Chief Medical Officer. Dr. Newmark is a board-certified urologist with over 30 years of experience managing Men’s Health issues, including benign prostatic hyperplasia (“BPH”). Blue Water currently owns ENTADFI®, an FDA-approved treatment for BPH that counteracts negat

Yahoo | April 26, 2023

Blue Water Biotech to Participate in the American Urological Association Annual Meeting 2023 to Promote Benign Prostatic Hyperplasia Treatment ENTADFI®

CINCINNATI, April 25, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”), a biotechnology company spanning multiple sectors, today announced that Blue Water management will attend the American Urological Association (“AUA”) Annual Meeting 2023 in Chicago, IL from April 28th to May 1st, 2023, to promote its asset ENTADFI®, an FDA-approved treatment for benign prostatic hyperplasia (“BPH”). Blue Water’s Chief Executive Officer, Joseph Hernandez, and Senior Vice Presi

Yahoo | April 25, 2023

Read More 'BWV' Stories Here

BWV Price Returns

1-mo -23.08%
3-mo -28.57%
6-mo -30.43%
1-year -79.22%
3-year N/A
5-year N/A
YTD -27.27%
2022 N/A
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!